Rocket Pharmaceuticals (NASDAQ:RCKT) Upgraded by Lifesci Capital to Strong-Buy Rating

Lifesci Capital upgraded shares of Rocket Pharmaceuticals (NASDAQ:RCKT) to a strong-buy rating in a research report released on Thursday,Zacks.com reports.

RCKT has been the topic of several other research reports. Cantor Fitzgerald boosted their price target on Rocket Pharmaceuticals from $8.00 to $10.00 and gave the company an “overweight” rating in a research note on Friday. JPMorgan Chase & Co. cut Rocket Pharmaceuticals from a “neutral” rating to an “underweight” rating in a report on Tuesday, November 18th. Wall Street Zen raised shares of Rocket Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Saturday. TD Cowen upgraded shares of Rocket Pharmaceuticals to a “hold” rating in a research report on Friday, December 19th. Finally, Morgan Stanley set a $5.00 price target on shares of Rocket Pharmaceuticals in a research report on Thursday, January 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $14.50.

Rocket Pharmaceuticals Price Performance

NASDAQ RCKT traded up $0.48 on Thursday, reaching $5.01. The company’s stock had a trading volume of 6,771,256 shares, compared to its average volume of 2,064,329. The firm has a market cap of $542.18 million, a PE ratio of -2.49 and a beta of 0.48. The business has a 50-day moving average price of $3.62 and a 200 day moving average price of $3.44. Rocket Pharmaceuticals has a 52 week low of $2.19 and a 52 week high of $9.73. The company has a current ratio of 7.30, a quick ratio of 7.30 and a debt-to-equity ratio of 0.06.

Rocket Pharmaceuticals (NASDAQ:RCKT) last announced its quarterly earnings results on Thursday, February 26th. The biotechnology company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.04. During the same quarter in the prior year, the firm posted ($0.62) EPS. Sell-side analysts expect that Rocket Pharmaceuticals will post -2.83 EPS for the current year.

Insider Activity

In related news, General Counsel Martin Wilson sold 12,253 shares of the company’s stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $3.31, for a total transaction of $40,557.43. Following the transaction, the general counsel owned 683,376 shares in the company, valued at $2,261,974.56. This represents a 1.76% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Gaurav Shah sold 12,279 shares of the firm’s stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $3.31, for a total transaction of $40,643.49. Following the completion of the sale, the chief executive officer owned 1,052,045 shares of the company’s stock, valued at $3,482,268.95. The trade was a 1.15% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 29,415 shares of company stock worth $97,398. 24.76% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Monaco Asset Management SAM raised its position in shares of Rocket Pharmaceuticals by 538.8% during the third quarter. Monaco Asset Management SAM now owns 2,892,261 shares of the biotechnology company’s stock worth $9,429,000 after acquiring an additional 2,439,494 shares during the last quarter. Amitell Capital Pte Ltd acquired a new stake in Rocket Pharmaceuticals in the second quarter worth about $556,000. Maverick Capital Ltd. raised its holdings in Rocket Pharmaceuticals by 60.9% during the 2nd quarter. Maverick Capital Ltd. now owns 8,363,813 shares of the biotechnology company’s stock worth $20,491,000 after purchasing an additional 3,164,595 shares during the last quarter. Bank of Montreal Can acquired a new position in Rocket Pharmaceuticals during the 2nd quarter valued at about $181,000. Finally, Virtus Investment Advisers LLC lifted its position in Rocket Pharmaceuticals by 134.6% during the 2nd quarter. Virtus Investment Advisers LLC now owns 30,630 shares of the biotechnology company’s stock valued at $75,000 after purchasing an additional 17,572 shares during the period. Institutional investors and hedge funds own 98.39% of the company’s stock.

Rocket Pharmaceuticals News Roundup

Here are the key news stories impacting Rocket Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital upgraded RCKT to a “Strong-Buy” and published a less negative FY2026 EPS forecast of ($1.81), well above the street consensus of ($2.83) — this reduces expected downside and supports investor confidence. Lifesci Capital note / MarketBeat
• Positive Sentiment: Cantor Fitzgerald raised its price target from $8 to $10 and kept an “Overweight” rating — a $10 PT implies roughly 100% upside from the recent price and can prompt momentum buying and coverage flows. Cantor Fitzgerald via Benzinga
• Positive Sentiment: RCKT reported Q4 EPS of ($0.38), beating the ($0.42) consensus and showing an improvement vs. last year’s ($0.62) loss. Management also provided pipeline updates — the narrower loss and progress on programs support the bull case for a clinical-stage biotech. Q4 press release
• Neutral Sentiment: Some outlets report the analyst consensus as an average “Hold” — mixed street views remain, so while upgrades are driving near‑term interest, broader analyst sentiment is still cautious. Analyst consensus report
• Neutral Sentiment: Wall Street Zen revised its stance to “Hold” — another signal of mixed opinions that could limit sustained rallies unless clinical or commercial news follows. Wall Street Zen article

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.

The company’s pipeline comprises multiple product candidates in various stages of development.